Do Peptides Help Hair, Skin, and Nails? What the Evidence Says

Some peptides help a little, and the honest answer depends on which peptide, which body part, and how it is delivered. A few topical peptides have small randomized trials showing modest improvement in fine lines, the largest being a 93-woman, 12-week study of palmitoyl pentapeptide. Oral collagen peptides look helpful in company-funded trials, but a 2025 meta-analysis of 23 trials found no skin benefit in independently funded studies. For hair and nails the evidence is thinner still. No peptide has evidence close to that of minoxidil or finasteride for hair loss, and no cosmetic or injectable peptide is FDA approved for hair, skin, or nails.

What "peptide" means, and why one word covers very different products

A peptide is a short chain of amino acids, the same building blocks that make up proteins. Your body uses many natural peptides as messengers: insulin is one, and so are many of the signals that tell skin cells to make collagen or to repair a wound. That biology is real, and it is why the word carries so much weight in marketing.

The trouble is that "peptides for hair, skin, and nails" describes at least three unrelated kinds of product. They reach the body by different routes, they are regulated under different rules, and the evidence behind them is not interchangeable. A result from one category tells you almost nothing about another.

Topical cosmetic peptides

These are the ingredients in serums and creams with names like palmitoyl pentapeptide-4, acetyl hexapeptide-8, and copper tripeptide-1. They are synthetic, usually between three and six amino acids long, and they are sold as cosmetics. Most of this article is about them, because they are what most people mean when they ask whether peptides work for skin.

Oral collagen peptides

Collagen peptides, also called hydrolyzed collagen, are made by breaking animal collagen into small fragments that dissolve in a drink. They are dietary supplements. The theory is that some fragments survive digestion, reach the bloodstream, and nudge skin cells to make more collagen. They have been tested for skin, nails, and more recently hair, with results covered below. For the wider picture on collagen, see the guide to what actually supports collagen production as you age.

Injectable peptides

A third category is peptides given by injection. These come either from compounding pharmacies or from peptide suppliers; neither route is FDA-reviewed. The same molecules are also sold by anonymous online sellers labeled "for research use only," with no physician involved. The best known in this space is the copper peptide GHK-Cu. As of September 2026, no injectable peptide is FDA approved for skin quality, hair growth, or nail health, and the FDA notes that there are limited data in humans to inform the safety of injected GHK-Cu. The regulatory details, and why the source matters, are in a later section.

Why the legal category matters to you

In the United States, the FDA defines a cosmetic as a product intended for cleansing, beautifying, promoting attractiveness, or altering the appearance. A drug is a product intended to treat or prevent disease or to affect the structure or any function of the body. The FDA states that cosmetic products and ingredients, other than color additives, do not need FDA approval before they go on the market.

That has two practical consequences. First, nobody has to prove to a regulator that a peptide serum works before selling it. Second, companies have a reason to keep claims vague. The FDA gives claims such as restoring hair growth or regenerating cells as examples that can turn a cosmetic into an unapproved drug. One industry review of cosmetic peptides notes this directly: proving a stronger biological effect might push an ingredient into the drug category, which manufacturers usually do not want. So the system quietly discourages the rigorous trials you would like to see.

The four classes of cosmetic peptides

Dermatology reviews sort topical peptides into four groups based on what they are designed to do. The scheme comes from a 2009 review by Gorouhi and Maibach at the University of California, San Francisco, and later reviews still use it.

Signal peptides

Signal peptides are fragments modeled on pieces of collagen, elastin, or other structural proteins of the skin. When collagen breaks down naturally, small fragments are released, and skin cells called fibroblasts read those fragments as a cue to build more. Signal peptides imitate that cue. The best studied is palmitoyl pentapeptide-4, sold under the trade name Matrixyl, whose five amino acid sequence (KTTKS) comes from the precursor of type I collagen. Others include palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and palmitoyl hexapeptide-12.

Carrier peptides

Carrier peptides bind a trace metal and are meant to deliver it to skin cells. The main example is copper tripeptide, GHK-Cu, a three amino acid peptide that occurs naturally in human plasma bound to copper. Trace metals such as copper are needed for wound healing and for enzyme activity in the skin. A manganese version exists but has only a single clinical study behind it. GHK-Cu has its own guide: what GHK-Cu is and what the research shows.

Neurotransmitter-inhibitor peptides

These are the "Botox-like" peptides. Expression lines form where facial muscles contract over and over. Muscles contract when a nerve ending releases the chemical messenger acetylcholine, and that release depends on a cluster of proteins called the SNARE complex. Botulinum toxin blocks that release. Acetyl hexapeptide-8 (also labeled acetyl hexapeptide-3, trade name Argireline) copies a stretch of one SNARE protein, SNAP-25, and is designed to get in the way of the complex forming. Related ingredients include pentapeptide-18 and a tripeptide modeled on a component of viper venom that blocks the muscle side of the signal.

Enzyme-inhibitor peptides

The fourth group is meant to slow the enzymes that break down collagen and other parts of the skin's support structure. Examples come from soy, rice, and silk proteins. This is the weakest class on evidence. The 2017 review by Schagen says plainly that very few or no human studies have been done for this group and that their relevance is still unclear.

The penetration problem: can a peptide get through your skin?

A peptide can only work if it reaches its target. For a signal peptide, the target is a fibroblast in the dermis, the deeper layer of skin. For a neurotransmitter inhibitor, the target is a nerve ending at a muscle, which sits deeper still. Between the jar and that target is the stratum corneum, the outermost layer of dead, flattened cells packed in fats. Its entire job is keeping things out.

The 500 dalton rule

In 2000, the dermatologists Bos and Meinardi proposed what is now called the 500 dalton rule. A dalton is a unit of molecular weight. They argued that a compound must be under 500 daltons to be absorbed through normal skin, and pointed out that virtually all common contact allergens, the most widely used topical medicines, and the drugs used in skin patches all fall under that limit.

Many cosmetic peptides are over the line. The KTTKS pentapeptide alone weighs about 564 daltons, and with its palmitoyl tail attached it is about 802 daltons. Peptides are also electrically charged and water loving, which makes it harder still to slip through a barrier made of fat. The rule is a rule of thumb, not a law. Schagen's review notes newer work suggesting larger molecules can cross, especially in dry or aged skin. But it sets a reasonable default expectation: most of what you apply stays near the surface.

How formulators try to get around it

The word "palmitoyl" on an ingredient list is the main workaround. It means a 16-carbon fatty acid has been attached to the peptide to make it more oil soluble. The effect can be large. Carnosine, a two amino acid peptide, has very little affinity for skin and does not get beyond the first layer of the stratum corneum, while its palmitoyl version diffuses into the stratum corneum, epidermis, and dermis, according to work summarized in Schagen's review. Other approaches include special delivery vehicles and small electrical currents, which are not part of ordinary skin care.

What an FDA laboratory found

The most direct test of the penetration question comes from the FDA's own scientists. Kraeling and colleagues applied a cosmetic emulsion containing 10% acetyl hexapeptide-8 to human cadaver skin and to hairless guinea pig skin in laboratory diffusion cells, then measured where the peptide went after 24 hours.

Most of it washed off the surface. In human skin, 0.22% of the applied dose was found in the stratum corneum and about 0.01% in the living epidermis beneath it. No peptide was detected in the dermis or in the fluid under the skin. This was a lab study of donated skin, not a trial in living people, but it matters: the ingredient is marketed as acting on nerve endings that lie below the dermis, and at a high 10% concentration it could not be detected even in the dermis.

What the skin trials actually show

There are real human trials of topical peptides. They share a pattern: small groups, short durations, instrument-measured endpoints such as wrinkle depth, and sponsorship by the company that makes the ingredient. Here is the best of the evidence by class.

Signal peptides: the strongest of a modest field

The largest published trial tested palmitoyl pentapeptide. Robinson and colleagues enrolled 93 Caucasian women aged 35 to 55 in a 12-week, double-blind, placebo-controlled, split-face study. Each woman applied a moisturizer containing 3 parts per million of the peptide to one randomly chosen side of her face and the same moisturizer without it to the other side. The peptide side showed a statistically significant reduction in wrinkles and fine lines by both computer image analysis and expert graders, and it was well tolerated.

That is a well-designed study, and the split-face design is a strength because each woman is her own control. Its limits are worth knowing. The authors worked for Procter and Gamble, which sells skin care. The abstract reports statistical significance but not how large the improvement was in terms a person would notice in a mirror. And it studied one skin type over three months.

Schagen's review lists other signal peptide studies, all smaller. A four-month double-blind study of 49 women found the same pentapeptide improved skin roughness, wrinkle volume, and wrinkle depth compared with the vehicle cream. A cream containing palmitoyl tripeptide-1 reduced wrinkle length and depth in a study of 15 women over four weeks, and in another study of 23 women it increased skin thickness by about 4% compared with the vehicle. A blend of two palmitoyl peptides sold as Matrixyl 3000 reduced wrinkle depth and volume in a randomized half-face study of 28 volunteers, a result reported in a patent filing, not a journal.

Carrier peptides: GHK-Cu

GHK-Cu has the most interesting biology of the group. It was discovered in 1973 by Loren Pickart, and his review reports that plasma levels fall from about 200 nanograms per milliliter at age 20 to about 80 by age 60. In cell and animal studies it increases the production of collagen, elastin, and other matrix components and supports wound repair.

The human skin data are cosmetic studies. In two 12-week studies, a GHK-Cu face cream used by 71 women and an eye cream used by 41 women with sun-damaged skin improved skin density and thickness and reduced fine lines, with the eye cream outperforming a placebo and a vitamin K cream. Another 12-week study of 67 women reported increased skin density and thickness. In a pilot study in which women applied creams to their thighs, collagen production increased in 70% of those using GHK-Cu, compared with 50% using vitamin C and 40% using retinoic acid.

Treat these numbers with care. They are described in review articles, and the main reviews are written by the peptide's discoverer, whose listed affiliation is a skin care company. Several of the original reports are hard to find in full, and a pilot study whose size the reviews do not report is a thin base for a claim that a peptide beats retinoic acid. The fair reading is that topical GHK-Cu is promising and reasonably well tolerated, and that it has not been tested in the kind of large independent trial that would settle the question.

Neurotransmitter inhibitors: "Botox in a jar"

The original Argireline paper, from Blanes-Mira and colleagues in 2002, reported that an emulsion containing 10% of the hexapeptide reduced wrinkle depth by up to 30% after 30 days in healthy women volunteers. Schagen's review gives the size of that study as 10 women. In cell experiments the peptide did inhibit neurotransmitter release, but the authors themselves noted it was much less effective than botulinum toxin.

A later randomized trial by Wang and colleagues assigned 60 Chinese adults in a 3 to 1 ratio to the peptide or a placebo, applied around the eyes twice daily for four weeks. By the investigators' global assessment, 48.9% of the peptide group improved compared with 0% of the placebo group, and measurements from silicone skin replicas showed reduced roughness. In a 43-woman comparison summarized in Schagen's review, wrinkle reduction was about 12% with pentapeptide-18, about 16% with acetyl hexapeptide, and about 25% with both together.

Why the nickname overstates it

Set those results beside the FDA laboratory finding that the peptide barely enters the living skin and never reached the dermis. Botulinum toxin is injected directly into the muscle for a reason. A cream that smooths the surface, holds water in the outer skin, and perhaps has some local effect can plausibly soften fine lines for a few weeks. None of the trials reviewed here shows a peptide cream relaxing a facial muscle the way an injection does, and the original authors themselves reported much lower efficacy than the toxin.

The limits that apply to all of these studies

• Small and short. Most trials enrolled 10 to 60 people for 4 to 12 weeks. None tracks results over years.
• Sponsored. The key studies were run or funded by ingredient makers or skin care companies. That does not make them wrong, but independent replication is rare.
• Mixtures. Schagen's review points out that many studies tested formulas that also contained niacinamide, vitamins C and E, or a moisturizer, so the peptide's own contribution cannot be separated out.
• Instrument endpoints. A statistically significant change in wrinkle depth on a profilometer may or may not be visible to you.
• Concentration unknown. The amount of peptide in a retail product is rarely disclosed and may not match what was tested.

Oral collagen peptides for skin, nails, and hair

Drinking collagen sidesteps the skin barrier but raises a different question: whether fragments of a digested protein can signal anything specific to skin, nail, or hair cells. The clinical trials give a mixed answer that depends heavily on who paid for the study.

Skin: positive trials, and a sobering re-analysis

Two frequently cited trials come from Proksch and colleagues in 2014. In the first, 69 women aged 35 to 55 were randomized to 2.5 grams or 5 grams of collagen hydrolysate or placebo daily for eight weeks. Skin elasticity improved significantly in both collagen groups compared with placebo, while changes in skin moisture did not reach statistical significance. In the second, 114 women aged 45 to 65 took 2.5 grams of a specific branded collagen peptide or placebo for eight weeks. Eye wrinkle volume fell by 20% compared with placebo, and skin fluid samples from a subgroup showed 65% more procollagen type I. Two authors of both trials are listed at the Collagen Research Institute in Kiel, Germany, on the group's later nail study, and the second trial tested a branded product.

A 2021 meta-analysis by de Miranda and colleagues pooled 19 randomized, double-blind trials with 1,125 participants, 95% of them women, and concluded that 90 days of hydrolyzed collagen reduced wrinkles and improved elasticity and hydration.

Then in 2025, Myung and Park published a meta-analysis in The American Journal of Medicine that asked a question earlier reviews had not: does the result depend on funding and study quality? Across all 23 trials and 1,474 participants, collagen improved hydration, elasticity, and wrinkles. But the trials that received no funding from pharmaceutical companies showed no effect on any of the three outcomes, while the company-funded trials did. High-quality studies likewise showed no significant effect. The authors concluded that there is currently no clinical evidence to support collagen supplements for skin aging. Collagen peptides may have a small real effect, or the positive results may mostly reflect sponsorship and weaker study design. Independent, well-run trials are what is missing.

Nails: one small uncontrolled study

The nail evidence is essentially one trial. Hexsel and colleagues gave 25 participants with brittle nails 2.5 grams of a branded collagen peptide daily for 24 weeks. Nail growth rate rose by 12%, the frequency of broken nails fell by 42%, and 64% of participants were judged to have a global improvement.

The study was open label with no placebo group, meaning everyone knew they were taking the product and there was no comparison. Nails also change with season, water exposure, and how they are handled. Two of the authors were from the Collagen Research Institute. This is a reason to run a proper trial, not proof that collagen strengthens nails.

Hair: early trials in people without hair loss

Until recently there were almost no controlled human data on collagen peptides and hair. Two randomized trials published in 2026 begin to fill that gap, with caveats. In one, Korean adults aged 19 to 60 with damaged hair but no alopecia (the medical term for hair loss) took 3 grams a day of a low-molecular-weight fish collagen peptide for 24 weeks. Compared with placebo, they had better hair gloss, tensile strength, and hair diameter. In the other, 114 women aged 20 to 50 with self-reported hair thinning took 1,000 milligrams a day of a similar product for 24 weeks, and hair shaft diameter increased significantly compared with placebo.

Both trials measured the quality of the hair shaft: shine, strength, thickness of individual strands. Neither measured hair counts, regrowth of lost hair, or any form of diagnosed alopecia, and both included authors from company research departments. They suggest collagen peptides might modestly improve the condition of existing hair. They say nothing about treating pattern hair loss.

Biotin: the myth, and the lab test problem

Biotin, vitamin B7, is not a peptide, but it sits next to peptides and collagen in almost every "hair, skin, and nails" product, so it belongs in this discussion. It is also the ingredient in this category with a documented safety issue.

What the evidence shows

The logic behind biotin supplements is that true biotin deficiency causes thinning hair, a scaly red rash, and brittle nails. The leap is assuming that extra biotin improves hair and nails in people who are not deficient.

The NIH Office of Dietary Supplements summarizes the evidence bluntly: the claims are supported, at best, by only a few case reports and small studies. For nails, there are three small studies, none with a placebo group and none reporting whether participants were deficient to begin with. In one, 2.5 milligrams a day increased nail thickness by 25% in eight women with brittle nails. In another, 41 of 45 patients (91%) reported firmer, harder nails after an average of 5.5 months. For hair, the NIH notes that only case reports exist, all in children with a rare hair shaft disorder.

A 2017 systematic review by Patel and colleagues reached the same conclusion from a different angle. It found 18 reported cases in which biotin improved hair or nails, and in every one the patient had an underlying condition such as an inherited enzyme deficiency or brittle nail syndrome. The authors found a lack of sufficient evidence for supplementation in healthy people.

Deficiency is rare

The adequate intake for adults is 30 micrograms a day. The NIH states that biotin deficiency is rare and that severe deficiency has never been reported in healthy people eating a normal mixed diet. Groups at higher risk include people with the inherited disorder biotinidase deficiency, people with chronic alcohol exposure, and pregnant or breastfeeding women. Long-term use of certain anti-seizure medicines is also linked to lower biotin levels.

One Swiss study by Trüeb reported low biotin levels in 38% of women who came in complaining of hair loss, which is sometimes quoted in support of supplements. Its author drew the opposite conclusion: giving biotin to women with hair loss indiscriminately should be rejected unless deficiency has been shown by history, examination, and a blood level. The American Academy of Dermatology goes further in its patient guidance, advising that biotin, iron, or zinc should be taken only when a blood test shows a deficiency.

How biotin interferes with blood tests

Many laboratory tests use a biotin and streptavidin reaction as part of their chemistry. Extra biotin in your blood sample can jam that reaction. Depending on how the test is built, the result can come back falsely high or falsely low, and nothing on the report flags the error.

The nail studies used 2.5 milligrams a day, and the authors of a JAMA study describe 10 milligrams as a dose common in over-the-counter supplements. Those amounts are roughly 80 to more than 300 times the adequate intake. In that JAMA study, six healthy adults took 10 milligrams a day for one week. Afterward, 9 of the 23 biotin-based tests examined (39%) gave distorted results, including falsely low thyroid-stimulating hormone, a pattern that can mimic an overactive thyroid, and falsely low NT-proBNP, a marker used to detect heart failure. The NIH notes that even a single 10 milligram dose has interfered with thyroid tests taken within 24 hours.

The most serious example involves troponin, the blood test used to diagnose a heart attack. The FDA first warned about biotin interference in November 2017, updated the warning in November 2019, and has said it continues to receive adverse event reports of falsely low troponin results caused by biotin. According to the NIH summary of the FDA's warning, a patient taking high-dose biotin died after a troponin test gave a falsely low result. The FDA maintains a public list of troponin tests that remain subject to this interference.

What this means in practice

• Tell every clinician and laboratory that you take biotin, including when it is part of a multi-ingredient hair, skin, and nails product or a multivitamin.
• Ask your doctor whether you should pause biotin before planned blood work, and for how long. Do not guess.
• If you ever go to an emergency department with chest pain, tell the staff about biotin supplements right away. Do not delay care to wait for biotin to clear.
• If a thyroid or hormone result does not fit how you feel, remind your doctor about biotin before anyone acts on the number.

How peptides compare with proven hair loss treatments

If thinning hair is what brought you here, the most useful comparison is with treatments that have been through large trials. A common cause is androgenetic alopecia, also called pattern hair loss, in which scalp follicles slowly shrink under the influence of androgen hormones.

Minoxidil

Topical minoxidil is sold over the counter. In a 48-week randomized, double-blind trial by Olsen and colleagues, 393 men applied 5% minoxidil, 2% minoxidil, or a placebo solution twice daily. The 5% solution was clearly superior to both, producing 45% more hair regrowth than the 2% solution at week 48, with more itching and local irritation at the higher strength. The American Academy of Dermatology notes that minoxidil can help early hair loss but cannot regrow a full head of hair, that results usually take about 6 to 12 months, and that the benefit is lost if you stop.

Finasteride

Finasteride is a prescription tablet that lowers dihydrotestosterone, the hormone that drives follicle shrinkage. In two one-year trials totaling 1,553 men aged 18 to 41, men taking 1 milligram a day had 107 more hairs than the placebo group in a one-inch circle of balding scalp after one year, and 138 more after two years, from a starting count of 876. Men on placebo continued to lose hair.

The FDA label states that finasteride is indicated for male pattern hair loss in men only. It is contraindicated in pregnancy because it can cause abnormalities of the genitals in a male fetus, and women who are or may be pregnant should not handle crushed or broken tablets. Three months or more of daily use is generally needed before a benefit shows, and stopping reverses the effect within 12 months. In the first year of the trials, 3.8% of men on finasteride reported a sexual side effect such as decreased libido or erectile dysfunction, compared with 2.1% on placebo. Reports received after approval include sexual dysfunction that continued after stopping, depression, and suicidal thoughts and behavior. The drug also lowers PSA, a prostate screening blood test, which your doctor needs to account for.

How the options rank

A 2022 network meta-analysis in JAMA Dermatology pooled 23 studies of minoxidil, finasteride, and dutasteride in men. It could rank the drugs against one another by change in hair count per square centimeter at 24 and 48 weeks, because every one of them had trials that counted hairs. Dutasteride 0.5 milligrams a day produced the greatest increase in total hair count at 24 weeks, and finasteride 1 milligram a day produced the greatest increase in terminal hair count at 48 weeks.

No topical or oral peptide could be included in an analysis like that, because comparable trials do not exist. A review written by industry-affiliated authors states that copper peptide increases hair growth and thickness and enlarges hair follicles, but it does not describe any randomized trial with hair counts to support that. The details are in the guide to whether GHK-Cu helps with hair growth.

On supplements more broadly, a 2023 systematic review in JAMA Dermatology examined 30 studies, 17 of them randomized trials, in people with hair loss and no known deficiency. It found potential benefit for several branded multi-ingredient products and for ingredients such as zinc and pumpkin seed oil, with rare and mild side effects, while calling for larger trials with active comparators. Biotin on its own does not appear in its summary list of interventions with the highest-quality evidence.

When hair loss needs a medical workup, not a product

Hair loss is a symptom with many causes, and no serum or supplement addresses all of them. Dermatologists diagnose it with a history, a close look at the scalp and nails, a gentle pull test, and sometimes blood tests or a scalp biopsy. It is worth seeing a doctor before buying products if you notice any of the following:

• Hair loss that came on suddenly or is progressing quickly
• Bald patches, or a scalp that is painful, itchy, red, or scaly
• Hair loss together with nail changes or other new symptoms

How long the loss has been going on and how fast it started are among the first things a dermatologist will ask, because the answers point toward different causes. A diagnosis first, then a product, is the order that saves both time and hair.

Injectable peptides for skin and hair: regulatory status

Interest in peptides has moved beyond creams to injections of peptides such as GHK-Cu. Here is what can be said with confidence as of September 2026.

• None is FDA approved. No injectable peptide has FDA approval for skin rejuvenation, hair growth, or nail health. Approval would require trials showing both safety and benefit, and those trials have not been done.
• The human evidence for GHK-Cu comes from topical use. The studies summarized above applied it to the skin. Results from a cream cannot be assumed to carry over to an injection, in either direction.
• Compounding status is unsettled. This concerns the compounding route specifically. Compounding pharmacies may only use bulk ingredients that meet certain legal criteria. The FDA had placed injectable GHK-Cu in Category 2, its list of nominated substances that raise significant safety concerns. According to the FDA's category list updated May 14, 2026, the nominations for GHK-Cu were withdrawn in April 2026, GHK-Cu for non-injectable routes was then returned to Category 1 (substances under evaluation), and the FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should be added to the list of substances that may be compounded.
• Leaving Category 2 is not an approval. It does not mean the FDA has found injectable GHK-Cu safe or effective. It means the question is going to an advisory committee.

The FDA's stated concern is specific. Its safety summary says compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity, meaning an unwanted immune reaction, because of the potential for the peptide to clump and for peptide-related impurities, and that there are limited data in humans to inform safety. That concern about impurities is the reason to care where an injectable peptide comes from. Injectable peptides come either from compounding pharmacies or from peptide suppliers; neither route is FDA-reviewed. The riskiest route is buying the same molecule from an anonymous online seller labeled "for research use only" and injecting it on your own, with no way to know what is in the vial, what dose you are taking, or who to call if something goes wrong. A physician-provided route adds what self-directed use lacks: an independent laboratory test for identity and purity on each batch, a certificate of analysis the patient can see, reconstitution in the office, written dosing instructions, and medical follow-up. None of that makes the product FDA-approved or changes the state of the evidence.

Rx2BFIT does not use a compounding pharmacy. Its injectable peptides come from a supplier whose batches are tested by an independent laboratory for identity and purity, with a certificate of analysis on file, and are reconstituted in the office under Dr. Patel's supervision. They are not FDA-approved products, no human trial supports them for skin or hair by injection, and that is reviewed with every patient before starting. An overview of the category is on the peptide therapy page.

Safety and side effects across the category

Topical peptides

The trials consistently describe topical peptides as well tolerated, and low irritation is their main practical advantage over retinoids and acids. Any cosmetic can still cause irritation or an allergic rash, often from fragrance or preservatives in the formula. Stop using a product that causes persistent redness, swelling, or itching. Swelling of the lips, face, or throat or trouble breathing after any product is an emergency.

Collagen and biotin supplements

Collagen trials report few or no side effects, though the trials are short. Collagen is animal derived, and the products in the 2026 hair trials came from fish, which matters if you have a fish allergy or dietary restrictions. Biotin has no established upper intake limit because no toxicity has been shown even at high doses. Its risk is the indirect one described above: a wrong lab result leading to a wrong medical decision.

Injections

Any injection carries risks that a cream does not: infection, bruising, and reactions at the injection site, plus the FDA's concern about immune reactions to peptide-related impurities, which applies to any injectable peptide because none of them is FDA-reviewed. Because human safety data on injected cosmetic peptides are so limited, the frequency of these problems is simply unknown. Seek urgent care for spreading redness, warmth, pus, or fever after an injection, or for hives, facial swelling, wheezing, or faintness.

How to read a peptide product claim

A few questions separate a reasonable product from a hopeful one.

1. Which peptide, exactly? "Peptide complex" tells you nothing. Look for a named ingredient you can search, such as palmitoyl pentapeptide-4.
2. Was the finished product tested, or just the ingredient? Many brands cite the ingredient supplier's study, which may have used a different concentration and base.
3. Tested against what? A comparison with untreated skin mostly measures the moisturizer. Look for a vehicle-controlled or placebo-controlled design.
4. In how many people, for how long? Ten people for 28 days is a pilot, not proof.
5. What was measured? "92% of users agreed their skin felt firmer" is a satisfaction survey, not an efficacy result.
6. Is the claim legal for a cosmetic? A cosmetic that promises to regrow hair or regenerate cells is making a drug claim without drug evidence.

Questions to ask your doctor

These questions apply to any option you are weighing, from a drugstore serum to a physician-supervised skin treatment such as a glow blend.

• What is causing my hair loss, brittle nails, or skin changes, and do I need any blood tests or a biopsy to find out?
• Which treatments for my specific diagnosis have been tested in randomized trials, and what result is realistic at 6 and 12 months?
• I take a supplement containing biotin. Should I stop it before my next blood tests, and for how long?
• If you are suggesting an injectable peptide, what human evidence supports it for my goal, what is its current FDA status, where does it come from, is each batch tested by an independent laboratory for identity and purity, and can I see the certificate of analysis?
• What side effects should make me stop and get in touch with you, and which ones need urgent care?
• If I am pregnant, planning pregnancy, or breastfeeding, which of these options are off the table?

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.